药物涂层球囊对比直接支架置入治疗新发冠心病的3年随访:REC-CAGEFREE I试验
REC-CAGEFREE I是一项在中国43个中心开展的非劣效性随机试验,纳入2272例新发冠心病患者,比较紫杉醇药物涂层球囊(DCB)联合补救支架与直接置入第二代薄梁西罗莫司洗脱支架(DES)的疗效。3年随访显示,DCB组设备导向复合终点(DOCE)发生率为8.2%,DES组为5.0%,差异有统计学意义(P=0.002),DCB策略未达到非劣效。
要点
- 对于新发冠心病,DCB联合补救支架在3年DOCE上劣于直接置入第二代DES。
- 3年时DCB组DOCE发生率8.2%,DES组5.0%,差异3.21%(95%CI 1.17%-5.26%)。
- DCB组仅9.4%患者需补救性DES置入,但整体临床结局仍较差。
核心结论
- 在新发冠心病患者中,与直接置入第二代薄梁西罗莫司洗脱支架相比,药物涂层球囊联合补救支架策略在3年时DOCE发生率更高。
研究设计与样本
- REC-CAGEFREE I为开放标签、随机、非劣效性试验,在中国43个中心开展。
- 共纳入2272例新发冠心病患者,1:1随机分配至DCB联合补救支架组(1133例)或直接DES组(1139例)。
- 主要终点为意向性治疗人群的设备导向复合终点(DOCE),包括心血管死亡、靶血管心肌梗死和临床及生理学指示的靶病变血运重建。
主要发现
- 3年时DCB组DOCE发生92例(8.2%),DES组56例(5.0%),差异3.21%(95%CI 1.17%-5.26%;P=0.002)。
- 界标分析显示0-1年、1-2年、2-3年的DOCE率差异分别为1.69%(95%CI 0.32%-3.06%)、1.10%(95%CI -0.13%至2.32%)、0.58%(95%CI -0.51%至1.66%),Ptrend=0.023。
- DCB组中106例(9.4%)在DCB血管成形术不满意后接受了补救性DES置入。
临床怎么用
- 对于新发冠心病患者,直接置入第二代DES仍是优先考虑的介入策略,DCB联合补救支架策略需谨慎选择。
- 若使用DCB策略,应预期补救支架的可能,并关注远期DOCE风险。
局限性
- 原文未明确报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Owing to the absence of a metallic scaffold, percutaneous coronary intervention (PCI) with drug-coated balloons (DCBs) may cause less chronic inflammation and potentially reduce late complications compared with drug-eluting stents (DES). However, in the REC-CAGEFREE I study, the strategy of DCB angioplasty with rescue stenting failed to achieve noninferiority to intended DES implantation for treating de novo lesions at 2 years. OBJECTIVES: This study sought to investigate the 3-year outcomes of the REC-CAGEFREE I trial and assess the mid-term effects of DCBs compared with DES. METHODS: REC-CAGEFREE I was an open-label, randomized, noninferiority trial conducted across 43 sites in China. After successful lesion predilation, 2,272 patients with de novo coronary artery disease (regardless of target vessel diameter) were randomly assigned (1:1) to paclitaxel-coated balloon angioplasty with the option of rescue stenting (DCB arm) vs up-front deployment of second-generation thin-strut sirolimus-eluting stents (DES arm). The primary outcome was the device-oriented composite endpoint (DOCE; including cardiovascular death, target vessel myocardial infarction [TV-MI], and clinically and physiologically indicated target lesion revascularization [CPI-TLR]) assessed in the intention-to-treat population. The extended follow-up is ongoing and will continue for up to 10 years. RESULTS: From February 5, 2021, to May 1, 2022, 1,133 patients were randomly assigned to the DCB arm and 1,139 to the DES arm. The median diameter of devices was at 3.00 ± 0.46 mm. Rescue DES implantation after unsatisfactory DCB angioplasty was performed in 106 patients (9.4%). At 3 years, the DOCE occurred in 92 patients (8.2%) in the DCB arm and 56 (5.0%) in the DES arm (difference: 3.21%; 95% CI: 1.17%-5.26%; P = 0.002). Landmark analyses showed that the rates of difference in the DOCE at 0 to 1, 1 to 2, and 2 to 3 years were 1.69% (95% CI: 0.32%-3.06%), 1.10% (95% CI: -0.13% to 2.32%), and 0.58% (95% CI: -0.51% to 1.66%), respectively (Ptrend = 0.023). CONCLUSIONS: In patients with de novo coronary artery disease, DCB angioplasty with rescue stenting was associated with a higher rate of the DOCE compared with up-front DES implantation regarding the DOCE at 3 years. (Paclitaxel-Coated Balloon for Treatment of De-Novo Noncomplex Coronary Artery Lesions; NCT04561739).
引用
- Tao L, He X, Shen G, et al. Drug-Coated Balloon Angioplasty vs Up-Front Stenting for De Novo CAD: 3-Year Follow-Up of REC-CAGEFREE I Trial. J Am Coll Cardiol. 2025. PMID: 41194754. doi:10.1016/j.jacc.2025.10.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。